BIOMAT Database Logo BIOMAT Database Logo

Phase I study of subcutaneously-administered bacterially-synthesised recombinant human granulocyte-macrophage colony-stimulating factor. 1992

G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Centre, New York, New York 10021.

A phase I study was initiated to test the effect of bacterially-synthesised recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). 15 patients with advanced cancers were entered into the study and 14 were evaluable. Patients were administered a single subcutaneous injection (3.0-300 micrograms/m2) of rhGM-CSF. Starting at a concentration of 100 micrograms/m2, an approximate 2-fold increase in leucocyte count was noted 24 h after the injection. By 48 h the counts had returned to baseline. The 300 micrograms/m2 concentration also induced an approximate 2-fold increase. The leucocytosis was associated with a predominant increase in circulating neutrophils and bands. An increase in monocytes was also noted, but peak levels were recorded 48-72 h after the injection. At both the 100 micrograms/m2 and the 300 micrograms/m2 doses, significant levels of circulating rhGM-CSF were detected. The levels measured in the plasma of patients receiving 300 micrograms/m2 were over 10-fold greater than those measured at 100 micrograms/m2. There was no detectable antibody formation against the rhGM-CSF in any of the study patients. The drug was exceptionally well-tolerated. This study shows that rhGM-CSF can be safely administered by subcutaneous administration and a single injection is capable of inducing a leucocytosis with increased circulating neutrophils, bands, and monocytes when doses are used which result in significant levels of circulating rhGM-CSF.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor

Related Publications

G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor.
August 1988, Behring Institute Mitteilungen,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
February 1990, Cancer research,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Phase I clinical study for recombinant human granulocyte colony-stimulating factor.
August 1988, Behring Institute Mitteilungen,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.
April 1989, Seminars in hematology,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor.
January 1987, Blood,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
August 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.
March 1989, Annals of internal medicine,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Single high-dose recombinant human granulocyte-macrophage colony stimulating factor: results of a phase I tolerability study.
January 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Treatment of chemotherapy-induced neutropenia in children with subcutaneously administered recombinant human granulocyte colony-stimulating factor.
January 1992, Pediatric hematology and oncology,
G K Schwartz, and J J Collins, and A Galazka, and P A Nessi, and D Lehrer, and Y Baldwin, and J Mandeli, and J F Holland
Recombinant human granulocyte-macrophage colony-stimulating factor produces fever.
April 1988, Lancet (London, England),
Copied contents to your clipboard!